Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an update.
Rhythm Biosciences Ltd. announced the cessation of 200,000 securities due to the lapse of conditional rights, as the conditions were not met by the expiration date of November 30, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the biotechnology industry, focusing on the development of diagnostic technologies. The company is primarily engaged in creating products for early detection of cancer, aiming to improve patient outcomes and reduce healthcare costs.
Average Trading Volume: 343,535
Technical Sentiment Signal: Buy
Current Market Cap: A$28.99M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.